Clinical Trial

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-25.
Trial Details
NCT Number NCT07327359
Lead Sponsor Olix Pharmaceuticals, Inc.
Collaborators: Avance Clinical Pty Ltd.
Conditions Androgenetic Alopecia (AGA)
Enrollment 158 participants
Start Date 2025-12-04
Primary Completion 2026-04 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-06